Written by and published on thechiefnavigators.com on August 29, 2023
Piet Hein van Dam is a seasoned entrepreneur with a strong background in health technology and data. He serves as the CEO and founder of Clear.bio, a company that has been experiencing rapid growth and driving transformative changes in the industry. Piet has a remarkable track record as a CEO, particularly with early-stage ventures, guiding them towards the next level of success. His expertise spans various sectors, including AdTech, MediaTech, HRTech, FinTech, and his current focus, HealthTech.
Notably, Piet Hein van Dam has achieved two successful exits, reflecting his ability to bring companies to fruition and create value. He is recognized for his exceptional intelligence (IQ), emotional intelligence (EQ), and execution quotient (XQ). In addition, his Gallup Signature Strengths—adaptability, Includer, Belief, Strategic, and activator—further enhance his leadership capabilities and drive for innovation.
Below are the highlights of the interview.
Tell us about Clear.bio and its mission. What inspired you to join this company?
Clear.bio is a healthtech start-up in Amsterdam, set up by Piet Hein van Dam and Madelon Bracke in 2019. Our mission is to help people with type 2 diabetes (T2D) to become the best and healthiest versions of themselves. With data instead of pills. And with the most modern technology and the latest nutritional science.
Clear.bio has developed a DTx to help people with T2D improve their health by making the right food choices. A sensor on their upper arm monitors their blood sugar in real time. In our app, they log everything they eat and drink. Our app immediately shows them how their blood sugar responds to food and provides them with nudges and guidance about which foods are or are not good for their body. It is 100% data-driven, 100% personal, and 100% actionable. By making small, smart changes to their food intake and with the help of our dieticians—always available one click away—they improve their blood sugar and health themselves, without any additional healthcare or medication.
The research into the clinical effectiveness of our new data-driven DTx has been realized in collaboration with the biggest Dutch health care insurer Zilveren Kruis Achmea, and the biggest Dutch patient association and social partner Diabetesvereniging Nederland and was under the supervision of the scientific advisory board consisting of internist-endocrinologist Maarten Soeters, PhD, from Amsterdam UMC and Georges Janssens, PhD, researcher and assistant professor of genetic metabolic diseases, from Amsterdam UMC.
As a healthcare provider, Clear.bio has already helped thousands of people with T2D become the best and healthiest versions of themselves. The investors behind Clear.bio are Antler, Healthy.Capital, Future Food Fund, MSM, AIF and Horizon Flevoland.
What strategies do you employ to ensure that Clear.bio remains competitive in the market?
Clear.bio uses personal glucometry as the core of its behavioral change technology. It’s the most powerful technique so far.
With the unique combination of a smart AI-app, real-time glucometry, and real dieticians, always available one click away, almost 70% of people with poorly regulated T2D are able to lower their eHbA1c by 11.6 mmol/mol (-1.1%) within 3 months. That’s better, cheaper, and faster than any local or international alternative.
Do you want to read the complete interview? Go to thechiefnavigators.com